title: Duration of vitamin K-antagonist treatment before DC cardioversion does not affect recurrence rate in patients with atrial fibrillation.
authors: Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Denmark. Electronic address: mads.nybo@ouh.regionsyddanmark.dk.
authors: M
authors: M
authors: Nybo
authors: C E
authors: CE
authors: Sørensen
authors: A E
authors: AE
authors: Budtz
authors: F L
authors: FL
authors: Henriksen
authors: A
authors: A
authors: Brandes
mesh_terms: D001281:Atrial Fibrillation / Q000628:therapy*; D003131:Combined Modality Therapy; D004554:Electric Countershock; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D014812:Vitamin K
keywords: Atrial fibrillation; Cardioversion; Outcome; VKA treatment